[go: up one dir, main page]

WO2009158284A9 - Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques - Google Patents

Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques Download PDF

Info

Publication number
WO2009158284A9
WO2009158284A9 PCT/US2009/048018 US2009048018W WO2009158284A9 WO 2009158284 A9 WO2009158284 A9 WO 2009158284A9 US 2009048018 W US2009048018 W US 2009048018W WO 2009158284 A9 WO2009158284 A9 WO 2009158284A9
Authority
WO
WIPO (PCT)
Prior art keywords
materials
methods
immune responses
antibiotic resistance
responses against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/048018
Other languages
English (en)
Other versions
WO2009158284A2 (fr
Inventor
Michael A. Barry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Original Assignee
Mayo Foundation for Medical Education and Research
Mayo Clinic in Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation for Medical Education and Research, Mayo Clinic in Florida filed Critical Mayo Foundation for Medical Education and Research
Priority to US13/001,228 priority Critical patent/US20110189217A1/en
Publication of WO2009158284A2 publication Critical patent/WO2009158284A2/fr
Publication of WO2009158284A9 publication Critical patent/WO2009158284A9/fr
Anticipated expiration legal-status Critical
Priority to US14/462,099 priority patent/US20140356395A1/en
Priority to US15/332,831 priority patent/US10143736B2/en
Priority to US16/173,953 priority patent/US20190046629A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2009/048018 2008-06-26 2009-06-19 Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques Ceased WO2009158284A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US13/001,228 US20110189217A1 (en) 2008-06-26 2009-06-19 Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
US14/462,099 US20140356395A1 (en) 2008-06-26 2014-08-18 Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
US15/332,831 US10143736B2 (en) 2008-06-26 2016-10-24 Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
US16/173,953 US20190046629A1 (en) 2008-06-26 2018-10-29 Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7588108P 2008-06-26 2008-06-26
US61/075,881 2008-06-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/001,228 A-371-Of-International US20110189217A1 (en) 2008-06-26 2009-06-19 Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
US14/462,099 Continuation US20140356395A1 (en) 2008-06-26 2014-08-18 Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance

Publications (2)

Publication Number Publication Date
WO2009158284A2 WO2009158284A2 (fr) 2009-12-30
WO2009158284A9 true WO2009158284A9 (fr) 2010-05-06

Family

ID=41445244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048018 Ceased WO2009158284A2 (fr) 2008-06-26 2009-06-19 Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques

Country Status (2)

Country Link
US (4) US20110189217A1 (fr)
WO (1) WO2009158284A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158284A2 (fr) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques
LT3106176T (lt) * 2011-12-06 2018-01-10 Valneva Austria Gmbh Aliuminio junginiai, skirti naudoti terapijoje ir vakcinose
WO2013135274A1 (fr) * 2012-03-13 2013-09-19 Intercell Ag Composés d'aluminium et agents thérapeutiques destinés à être utilisés dans des vaccins
KR20140116095A (ko) * 2011-12-12 2014-10-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Mrsa pbp2a 및 이의 단편들을 포함하는 단백질, 이를 인코딩한 핵산, 및 mrsa 감염을 예방 및 치료하기 위한 조성물 및 그의 용도
US9169477B2 (en) 2012-01-27 2015-10-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for immunization against bacteria expressing a carbapenemase
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
CN110777154A (zh) * 2019-07-19 2020-02-11 华大生物科技（武汉）有限公司 用于结核分枝杆菌耐药检测的突变基因、及其检测方法和试剂盒
US12267062B2 (en) 2020-06-17 2025-04-01 Murata Manufacturing Co., Ltd. Transversely-excited film bulk acoustic resonators with three-layer electrodes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686590A (en) * 1993-05-14 1997-11-11 Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. Methods and compositions for detecting and treating mycobacterial infections using an INHA gene
EP0892055A3 (fr) * 1997-07-01 2002-03-20 Smithkline Beecham Corporation Polypeptides GidB de Staphylococcus aureus
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
CA2508726A1 (fr) * 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Procedes d'identification rapide de pathogenes chez l'homme et les betes
AU2006243357B2 (en) * 2005-04-29 2012-03-15 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M tuberculosis infection
US9717788B2 (en) * 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
US20110105531A1 (en) * 2007-06-22 2011-05-05 Ibis Biosciences, Inc. Compositions and methods for identification of subspecies characteristics of mycobacterium tuberculosis
US9598737B2 (en) * 2012-05-09 2017-03-21 Longhorn Vaccines And Diagnostics, Llc Next generation genomic sequencing methods
RU2559782C2 (ru) * 2007-12-17 2015-08-10 Марфл Аб Набор для детекции спор, происходящих из микобактерий
US10131921B2 (en) * 2008-03-06 2018-11-20 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
WO2009158284A2 (fr) * 2008-06-26 2009-12-30 Mayo Foundation For Medical Education And Research Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques
PT2315834T (pt) * 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa A proteína rv2386c de tuberculose, composições e as suas utilizações
KR100943302B1 (ko) * 2009-03-11 2010-02-23 다이노나(주) 메치실린-내성 황색포도상구균 특이적 항체, 상기 항체를 이용하는 메치실린 내성 황색포도상구균 탐지방법, 및 탐지키트
US8367055B2 (en) * 2009-05-14 2013-02-05 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
GB201002413D0 (en) * 2010-02-12 2010-03-31 Procarta Biosystems Ltd Nucleic acid complexes
GB201008719D0 (en) * 2010-05-25 2010-07-07 Nat Univ Ireland Diagnostic method
CN102887952A (zh) * 2011-07-21 2013-01-23 广州瑞博奥生物科技有限公司 具有双重结合活性的抗MRSA-PBP 2a的单克隆抗体
KR20140116095A (ko) * 2011-12-12 2014-10-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Mrsa pbp2a 및 이의 단편들을 포함하는 단백질, 이를 인코딩한 핵산, 및 mrsa 감염을 예방 및 치료하기 위한 조성물 및 그의 용도
US10508311B2 (en) * 2013-08-26 2019-12-17 The Translational Genomics Research Institute Single molecule-overlapping read analysis for minor variant mutation detection in pathogen samples
US20160074480A1 (en) * 2015-11-24 2016-03-17 Totada R. Shantha Innovative methods of treatmenting tuberculosis

Also Published As

Publication number Publication date
US20110189217A1 (en) 2011-08-04
US10143736B2 (en) 2018-12-04
US20140356395A1 (en) 2014-12-04
WO2009158284A2 (fr) 2009-12-30
US20170035873A1 (en) 2017-02-09
US20190046629A1 (en) 2019-02-14

Similar Documents

Publication Publication Date Title
WO2009158284A9 (fr) Méthodes et matériaux de production de réponses immunitaires contre des polypeptides impliqués dans la résistance aux antibiotiques
EP2240056B8 (fr) Article présentant une finition non collante et une résistance améliorée aux rayures
EP2362738A4 (fr) Ensembles de préparation culinaire et procédés s y rapportant
EP2193097A4 (fr) Articles composites renforcés par des nanostructures et procédés correspondants
PT2606145T (pt) Métodos para determinar resistência antibiótica em microrganismos
IL202183A0 (en) Anti-notch1 nrr antibodies and methods using same
IL195681A0 (en) Impact resistive composite materials and methods for making same
TWI348716B (en) Resistive component and making method thereof
EP2133086A4 (fr) Procédé de préparation de sérum et appareil de préparation de sérum
GB0802474D0 (en) Mutant proteins and methods for selecting them
GB0605702D0 (en) Materials and methods for immune cell stimulation
WO2009006359A8 (fr) Anticorps anti-mcp-1, compositions, procédés et utilisations
IL200019A0 (en) Polypeptide films and methods
GB0901109D0 (en) Mutant proteins and methods for selecting them
AU2008902600A0 (en) Polypeptides and uses thereof
AU2007902971A0 (en) Receptors and related methods and products
AU2007904052A0 (en) Materials and production methods
AU2006901344A0 (en) Materials and methods
HK1148683A (en) Materials and methods for improved immunoglycoproteins
HK1170538A (en) Novel antibodies and their uses in therapeutic and diagnostic methods
AU2006900573A0 (en) Improvements in seating
AU2007905486A0 (en) Composition and method
AU2007905485A0 (en) Composition and method
AU2007905574A0 (en) Composition and Method
AU2007900335A0 (en) Improvements in aircraft

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770818

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13001228

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09770818

Country of ref document: EP

Kind code of ref document: A1